This is a preview of subscription content, log in via an institution to check access.
Notes
WHO recently issued new guidelines recommending initiation of ART in HIV-infected adults when CD4 count is ≤ 500 cells/µL; see PharmacoEconomics & Outcomes News 682 p2; 809151479
Reference
Eaton JW, et al. The epidemiological impact and cost-effectiveness of expanded eligibility for and access to adult antiretroviral therapy in South Africa, Zambia, India and Vietnam: a twelve model analysis. 7th International AIDS Society Conference on HIV Pathogenesis and Treatment : abstr. MOAC0203, 30 Jun 2013.
Rights and permissions
About this article
Cite this article
Expanding ART eligibility could be cost effective. PharmacoEcon Outcomes News 683, 5 (2013). https://doi.org/10.1007/s40274-013-0570-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0570-8